Arshi Syal, MD

Words cannot describe my happiness. I am one step closer to my dream of providing the most compassionate cancer care to our patients. The best part is that I get to embark on this wonderful journey with my fiancé at our top choice for fellowship at Mayo Clinic Fl @MayoCancerCare

Had an amazing time presenting my poster and attending ASCO, 25! My last one as a resident. Can’t wait to be back next year as a fellow & a shoutout to my amazing soon to be co-fellows! @yajur_arya @Meddoc77 @NityaBatra3 #ASCO25 #MedTwitter @ElvisObomanu

Just wrapped up an incredible experience presenting at ASCO. Grateful for the opportunity to meet and connect with friends, mentors, and pioneers in the field. Excited for starting fellowship soon! #ASCO2025 @IMG_Oncologists @Arshi_Syal @Meddoc77 @NityaBatra3 @ElvisObomanu

The best part about #ASH24! Absolutely thrilled to finally meet the legend @AaronGoodman33. You are an inspiration! Big thanks for the taco recs! 🌮

Amazing first day at #ASH24 @JeffHealthEH @JCL_HemeOnc @IMG_Oncologists @ASH_hematology

So excited to be at #ASH24. Sharing some snippets from day 1. Looking forward to another poster presentation tomorrow! @ASH_hematology @IMG_Oncologists @JeffHealthEH

Presenting today @ #ASH24

Excited to be back at #ASH24. Can’t believe its been an year already. So many spectacular sessions!! @yajur_arya @JeffHealthEH @IMG_Oncologists @ASH_hematology

🎉Excited to share our work👉Guide to understanding & supporting #IMGs in Hematology & Oncology by @ASCO #IMGCoP Focusing on challenges faced by IMGs and solutions to improve their journey🌟 👉tinyurl.com/2su6r8zx @NazliDizman @ZiadBakouny @DrChoueiri @OncoAlert @ASCOTECAG

Another successful CHEST2024 - @Arshi_Syal oncodaily.com/blog/162282 #Cancer #CancerAwareness #CancerCare #CHEST2024 #OncoDaily #Oncology #MedEd #MedX #MedNews #Medicine #Health

Had an amazing time at #CHEST2024 Honored to present my research! ✔️Oral presentation: Lung Cancer Outcomes ✔️5 first author poster presentations ✔️Invaluable networking & learning opportunities Boston, you will be missed! ⭐️ Next stop: ASH’24. See you there!

Another successful #CHEST2024 📍Boston ✔️2 Oral presentations 🟢Lung Cancer Outcomes 🟢Sickle cell disease, Vaso-occlusive crisis and outcomes ✔️9 Posters & 4 First Author ✔️Meeting & connecting with so many amazing people. Thank you everyone who made this a success!

🎉Immensely excited and proud to share with you our recent paper "Guide to Understanding and Supporting #InternationalMedicalGraduates in #Hematology #Oncology" with gratitude to my co-first author @ZiadBakouny, senior authors @DrChoueiri #DrAlfredLee, and other world-renowned…

Doing good science is 90% finding a science buddy to constantly talk to about the project.

🚨🔥 @OncoAlert Hot off the press. As expected, based on results of #Checkmate77T, @US_FDA approved #Neoadjuvant #Nivolumab +Chemo followed by #Adjuvant Nivolumab (after surgery) for pts with resectable Stage IIA-IIIB #NSCLC with no EGFR/ALK mutations. 👇🏼 fda.gov/drugs/resource…

Ipilimumab/nivolumab vs standard care in non-clear cell renal cell cancer by @apolo_andrea - @PGrivasMDPhD @schmidingerRCC @myESMO oncodaily.com/blog/144562 #Cancer #OncoDaily #Oncology #ESMO #RenalCellCancer #MedEd #MedX #MedNews #Medicine #Health

Remember sitting in the audience @ASCO when the early data for this #melanoma trial was presented to gasps and applause? To now see this flat OS at 10+ yrs - incredible! Kudos @bmsnews, site PIs and patients for committing to reporting long term OS. So important!

🔥🚨@OncoAlert Hot off the press. @US_FDA approves #Pembrolizumab plus #Chemothetapy (#Platinum + #Pemetrexed) for 1st line #Treatment of advanced unresectable #Pleural #Mesothelioma. Approval based on #Keynote 483 study: ✅⬆️#OS: HR: 0.79 👇🏼 shorturl.at/ukg4P